CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 53 filers reported holding CYTOSORBENTS CORP in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $53,301 | +70032.9% | 75,820 | -4.8% | 0.00% | – |
| Q1 2024 | $76 | -61.0% | 79,620 | -54.6% | 0.00% | – |
| Q4 2023 | $195 | -12.9% | 175,320 | +47.2% | 0.00% | – |
| Q3 2023 | $224 | -47.5% | 119,100 | +0.2% | 0.00% | -100.0% |
| Q2 2023 | $427 | +6.8% | 118,900 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $400 | +117.4% | 118,600 | +0.2% | 0.00% | – |
| Q4 2022 | $184 | -99.9% | 118,400 | -40.1% | 0.00% | – |
| Q3 2022 | $269,000 | -12.4% | 197,796 | +41.2% | 0.00% | – |
| Q2 2022 | $307,000 | +13.3% | 140,120 | +65.0% | 0.00% | – |
| Q1 2022 | $271,000 | -74.4% | 84,900 | -39.4% | 0.00% | -100.0% |
| Q2 2021 | $1,058,000 | -32.3% | 140,100 | -22.2% | 0.00% | -50.0% |
| Q1 2021 | $1,562,000 | +167.9% | 180,000 | +146.2% | 0.00% | +100.0% |
| Q4 2020 | $583,000 | -23.9% | 73,100 | -23.9% | 0.00% | 0.0% |
| Q3 2020 | $766,000 | +160.5% | 96,000 | +147.4% | 0.00% | – |
| Q1 2019 | $294,000 | -70.1% | 38,800 | -68.1% | 0.00% | -100.0% |
| Q4 2018 | $983,000 | -62.6% | 121,700 | -47.2% | 0.00% | 0.0% |
| Q2 2018 | $2,625,000 | – | 230,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skylands Capital, LLC | 1,772,000 | $13,379,000 | 1.58% |
| Sargent Investment Group, LLC | 856,315 | $6,465,000 | 1.53% |
| Avenir Corp | 1,366,549 | $10,317,000 | 0.82% |
| CM Management, LLC | 150,000 | $1,133,000 | 0.82% |
| Winning Points Advisors, LLC | 136,900 | $1,035,000 | 0.78% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 185,000 | $1,397,000 | 0.46% |
| SECTORAL ASSET MANAGEMENT INC | 244,660 | $1,847,000 | 0.15% |
| Redmile Group, LLC | 1,304,369 | $9,848,000 | 0.15% |
| Granahan Investment Management | 1,003,546 | $7,577,000 | 0.14% |
| ACT CAPITAL MANAGEMENT, LLC | 35,000 | $265,000 | 0.14% |